Long-Term Survival and Failure Outcomes of Single-Fraction Stereotactic Body Radiation Therapy in Early Stage NSCLC.
JTO Clin Res Rep
; 4(12): 100598, 2023 Dec.
Article
in En
| MEDLINE
| ID: mdl-38124792
ABSTRACT
Introduction:
This study aims to report our 13-year institutional experience with single-fraction stereotactic body radiation therapy (SF-SBRT) for early stage NSCLC.Methods:
A single-institutional retrospective review of patients with biopsy-proven peripheral cT1-2N0M0 NSCLC undergoing definitive SF-SBRT between September 2008 and May 2022 was performed. All patients were treated to 27 Gy with heterogeneity corrections or 30 Gy without. Primary outcomes were overall survival and progression-free survival. Secondary outcomes included local failure, nodal failure, distant failure, and second primary lung cancer.Results:
Among 263 eligible patients, the median age was 76 years (interquartile range [IQR] 70-81 y) and median follow-up time was 27.2 months (IQR 14.25-44.9 mo). Median tumor size was 1.9 cm (IQR 1.4-2.6 cm), and 224 (85%) tumors were T1. There were 92 patients (35%) alive at the time of analysis with a median follow-up of 34.0 months (IQR 16.6-50.0 mo). Two- and five-year overall survival was 65% and 26%, respectively. A total of 74 patients (28%) developed disease progression. Rates of five-year local failure, nodal failure, distant failure, and second primary lung cancer were 12.7%, 14.7%, 23.5%, and 12.0%, respectively.Conclusions:
Consistent with multiple prospective randomized trials, in a large real-world retrospective cohort, SF-SBRT for peripheral early stage NSCLC was an effective treatment approach.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
JTO Clin Res Rep
Year:
2023
Document type:
Article
Country of publication:
United States